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Highlights: 
• Steroid profiling used for random forest modelling of micro-APA, macro-APA and BAH  
• High accuracy for macro-APA and BAH, low accuracy for micro-APA classification  
• Micro-APA classification improved using novel diagnostic algorithm  
• Potential use to select patients with micro-APA for mandatory AVS 
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Abstract 
In primary aldosteronism (PA) the differentiation of unilateral aldosterone-producing adenomas 
(APA) from bilateral adrenal hyperplasia (BAH) is usually performed by adrenal venous sampling 
(AVS) and/or computed tomography (CT). CT alone often lacks the sensitivity to identify micro-
APAs. Our objectives were to establish if steroid profiling could be useful for the identification of 
patients with micro-APAs and for the development of an online tool to differentiate micro-APAs, 
macro-APAs and BAH. The study included patients with PA (n=197) from Munich (n=124) and 
Torino (n=73) and comprised 33 patients with micro-APAs, 95 with macro-APAs, and 69 with BAH. 
Subtype differentiation was by AVS, and micro- and macro-APAs were selected according to 
pathology reports. Steroid concentrations in peripheral venous plasma were measured by liquid 
chromatography-tandem mass spectrometry. An online tool using a random forest model was built for 
the classification of micro-APA, macro-APA and BAH. Micro-APA were classified with low 
specificity (33%) but macro-APA and BAH were correctly classified with high specificity (93%). 
Improved classification of micro-APAs was achieved using a diagnostic algorithm integrating steroid 
profiling, CT scanning and AVS procedures limited to patients with discordant steroid and CT results. 
This would have increased the correct classification of micro-APAs to 68% and improved the overall 
classification to 92%. Such an approach could be useful to select patients with CT-undetectable micro-
APAs in whom AVS should be considered mandatory. 
 
Keywords: primary aldosteronism, aldosterone-producing adenoma, Conn syndrome, bilateral adrenal 
hyperplasia, adrenal cortex, steroid profiling 
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Abbreviations: 17-OH-progesterone, 17-hydroxyprogesterone; 18OH-cortisol, 18-hydroxycortisol; 
APA, aldosterone-producing adenoma; ARR, aldosterone-to-renin ratio; AVS, adrenal venous 
sampling; BAH, bilateral adrenal hyperplasia; CT, computed tomography; CYP11B1, 11β-
hydroxylase; CYP11B2, aldosterone synthase; CYP17A1, 17α-hydroxylase; DHEA, 
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; HSD3B2, 3β-hydroxysteroid 
dehydrogenase type 2; H&E, hematoxylin and eosin; LC-MS/MS, liquid chromatography-tandem 
mass spectrometry; Macro-APA, macro-aldosterone-producing adenoma; Micro-APA, micro-
aldosterone-producing adenoma; MRA, mineralocorticoid receptor antagonist; OR, odds ratio; PA, 
primary aldosteronism.  
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1. Introduction 
Primary aldosteronism (PA) is the most frequent form of endocrine hypertension characterized by 
aldosterone overproduction relative to suppressed plasma renin [1-3]. Patients with PA have an 
increased risk of cardiovascular and cerebrovascular events and renal disease progression relative to 
patients with primary hypertension including those with similar cardiovascular risk profiles [4-7]. This 
highlights the importance of early diagnosis and appropriate clinical management to minimize 
detrimental cardiovascular outcomes.  
Unilateral PA is mainly caused by an aldosterone-producing adenoma (APA) and is potentially 
curable by laparoscopic unilateral adrenalectomy whereas bilateral PA (bilateral adrenal hyperplasia 
[BAH]) is usually treated with a mineralocorticoid receptor antagonist (MRA). These specific 
treatment options emphasize the central role of an accurate differentiation of APA from BAH in the 
diagnostic work up of PA which is usually performed by computed tomography (CT) and adrenal 
venous sampling (AVS) [8]. The sensitivity of CT imaging is often insufficient for the identification of 
APAs less than 10 mm in diameter, while AVS displays high sensitivity and specificity (95% and 
100%, respectively) to distinguish unilateral from bilateral PA [9, 10]. AVS is a technically-
demanding and invasive procedure with non-standardized protocols and variable interpretation of 
results, and alternative approaches to reduce or even replace AVS for subtype differentiation in PA are 
currently sought [11-16]. 
Various definitions of size of micro-APAs have been used which usually consider the CT-undetectable 
feature [9, 17-20]. Micro-APAs have been classified as < 10 mm in diameter, although in certain 
circumstances, ie, localization in an expanded adrenal limb, micro-APAs of 6 mm in diameter have 
been detected by CT [17]. CYP11B2 (aldosterone synthase) expression per tumour area by 
immunohistochemistry has been reported as higher in micro-APAs compared with macro-APAs 
together with a higher reported capacity for aldosterone production per tumour area [21]. CT-
undetectable micro-APAs have a reported prevalence of 13% to 30% in patients with APAs [9, 17-20] 
and therefore comprise a significant proportion of patients with APAs with potentially distinctive 
adrenal steroid profiles and clinical outcomes.  
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In the present study, we determined the liquid chromatography-tandem mass spectrometry (LC-
MS/MS)-based steroid profiles of peripheral venous plasma samples from patients with micro-APAs 
(< 10 mm in diameter), macro-APAs (≥ 10 mm in diameter) and BAH. Our objectives were to 
establish if steroid profiling could be useful to select patients with micro-APAs in whom AVS should 
be considered mandatory and determine if a diagnostic algorithm that integrates steroid profiling could 
help rationalize the use of AVS procedures in patients with PA. 
2. Subjects and methods 
The subjects included in this study were 197 patients diagnosed with PA from two referral centers 
(124 patients from Medizinische Klinik IV, Klinikum der Ludwig-Maximilians-Universität München, 
Munich, Germany and 73 patients from Division of Internal Medicine and Hypertension, University of 
Turin, Turin, Italy). The study was approved by the appropriate institutional ethics committees and 
written informed consent was obtained from all patients.  
2.1 Diagnosis and treatment 
PA was diagnosed in both Munich and Torino in accordance with the Endocrine Society Clinical 
Guideline using the aldosterone-to-renin ratio (ARR) as a screening test, confirmatory testing by saline 
infusion testing and subtype differentiation by AVS. Detailed methods for the diagnosis of PA and 
AVS procedures are described elsewhere [10, 22]. In all patients, AVS procedures were performed 
under basal conditions and successful catheterization was defined with a selectivity index (adrenal 
vein to peripheral cortisol ratio) ≥ 2.0. Unilateral PA was defined by a lateralization ratio (dominant to 
contralateral aldosterone-to-cortisol concentration ratio) ≥ 4.0. 
2.2 Classification of micro-APAs and macro-APAs and assessment of postoperative outcomes 
Pathology reports were used for an assessment of the diameter of the largest nodule in resected 
adrenals for an initial classification of adenomas as micro-APAs or macro-APAs.  Macro-APAs were 
defined by the largest nodule diameter ≥10 mm from pathology reports alone. Micro-APAs, from the 
initial assessment from pathology reports, were then analysed by CYP11B2 immunohistochemistry 
[23] and this group included either a single microadenoma with CYP11B2 immunostaining (diameter 
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<10 mm) or the largest nodule (with diameter <10 mm) in an adrenal with more than 1 nodule with 
CYP11B2 immunostaining (Figure 1). Cases of diffuse hyperplasia were excluded. Several adrenals 
showed aldosterone-producing cell clusters which are defined as tight clusters of cells with strong 
CYP11B2 immunostaining with zona glomerulosa morphology located beneath the capsule and 
extending into the zona fasciculata [24, 25]. The follow-up data of clinical and biochemical 
parameters were obtained in the surgically treated patients at 6-12 months. Outcomes were defined as 
complete, partial and absent clinical and biochemical success based on blood pressure measurements 
and antihypertensive medication dosage for clinical outcomes or plasma potassium and hormonal 
(aldosterone and renin) measurements for biochemical outcomes [26].  
2.3 Genotyping and gene expression analysis 
Genomic DNA was extracted from frozen adrenal tissues and DNA fragments of KCNJ5, ATP1A1, 
ATP2B3 and CACNA1D were amplified by PCR using the primers shown in Table A.1, supplementary 
data and sequenced as described [27, 28]. To our knowledge, PCR amplifications using these primers 
potentially identify all somatic APA mutations in the above genes described to date including the APA 
mutations described in CACNA1D listed in Prada et al [29], with the exception of CACNA1D 
Glu412Asp, and the new CACNA1D mutation described recently by Nanba et al [30]. 
Total RNA was extracted from adrenal tissues (tumours and adjacent cortex) and reverse transcribed 
as described previously [27]. Real-time PCR was performed in duplicate using TaqMan gene 
expression assays, and expression levels of CYP11B2 were analyzed by 2-∆∆Ct relative quantification 
using GAPDH as the endogenous reference gene. All samples were included in the gene expression 
analysis with available adenoma and corresponding adjacent cortical tissue (8 micro-APAs and 32 
macro-APAs). CYP11B2 gene expression analysis indicated an absence of CYP11B2 upregulation in 1 
of the 8 samples classified as micro-APAs (tumour-to-adjacent tissue CYP11B2 expression ratio = 
0.934; genotype determined as wild type) and in 1 of 32 samples classified as macro-APAs (tumour-
to-adjacent tissue CYP11B2 expression ratio = 0.926, genotype determined as wild type). This 
indicates the missed dissection of the CYP11B2 positive nodule for the micro-APA and the dissection 
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of a nonfunctional adenoma as the largest nodule for the sample classified as a macro-APA (Figure 
A.1, Supplementary data). 
2.4 Immunohistochemistry and immunohistochemical characterization 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections (3µm) 
with an anti-CYP11B2 antibody (dilution 1:200, mouse monoclonal anti-human antibody, clone 17B, 
from Dr Celso E. Gomez-Sanchez) [23] as described previously [31].  
 
2.5 LC-MS/MS-based steroid profiling 
Steroid profiling of peripheral venous plasma was done by LC-MS/MS as described in full elsewhere 
[32] for the simultaneous  measurement of 15 steroids [aldosterone, 18-oxocortisol, 18-
hydroxycortisol (18OH-cortisol), 21-deoxycortisol, corticosterone, 11-deoxycorticosterone, 
progesterone, cortisol, cortisone, 11-deoxycortisol, 17-hydroxyprogesterone (17-OH-progesterone), 
pregnenolone, androstenedione, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone 
sulphate (DHEAS)]. 
 
2.6 Statistical analyses 
Quantitative normally distributed variables are expressed as means with SDs and quantitative non-
normally distributed variables are reported as medians and interquartiles. Categorical variables are 
presented as absolute numbers and percentages. Comparisons between two groups were assessed by a 
t test or a Mann-Whitney test; multiple comparisons were assessed by ANOVA followed by 
Bonferroni test for pairwise comparisons, or Kruskal-Wallis test with pairwise comparisons. Chi-
square and Fisher’s exact tests were used to compare categorical data. A logistic regression analysis 
identified steroids associated with micro-APAs compared with macro-APAs and BAH with odds 
ratios (OR) for steroids calculated per ng/mL. An OR greater than 1 indicates an increased likelihood 
of micro-, macro-APAs or BAH, and an OR less than 1 indicates a decreased likelihood. IBM SPSS 
Statistics version 25.0 were used for statistical analyses. P values are given to three decimal places and 
are considered significant when P < 0.05.  
2.7 Predictive model 
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Random forest algorithms were performed using MATLAB R2017b and PYTHON 2.7 to assess how 
concentrations of steroids in peripheral venous plasma could be used to classify micro-, macro-APAs 
and BAH. The prediction model can be used via an online tool which requires operating system 
Windows version 64-bit or higher and is available at https://github.com/ABurrello/Steroid-profiling-
in-PA/archive/master.zip. Instructions are provided and the password is: MicroAPA_JBAB (requested 
just before entering steroid concentrations). Please note that the password protection will be removed 
upon eventual publication  
 
3. Results 
3.1 Patient characteristics, outcomes and immunohistochemical characterization 
Demographic and clinical characteristics at study entry and post-operative follow-up of all patients are 
shown in Table A.2 (Supplementary data). There was an overall difference in this cohort in the sex 
distribution of micro- and macro-APAs and BAH (P<0.001) with micro-APAs and BAH more 
prevalent in men than in women (micro-APAs: 78.8% vs 21.2%; BAH: 73.9% vs 26.1%). Patients 
with macro-APAs displayed the highest baseline concentrations of plasma aldosterone (P<0.001) and 
the lowest serum potassium concentrations (P<0.001) relative to the micro-APA or BAH group.  
Micro-APAs displayed a lower prevalence of somatic KCNJ5 mutations (3.2% vs 47.4%, P<0.001) 
and a higher proportion of the wild-type genotype (80.7% vs 36.2%, P<0.001) compared with macro-
APAs.  
 
Complete clinical and biochemical success were less frequent in the micro-APA than in the macro-
APA group (12.1% vs 40.0%, P=0.003, 84.8% vs 96.8%, P=0.023, respectively) whereas absent 
biochemical success was more prevalent in the micro-APA group (9.1% vs 1.1%, P=0.036). In total, 8 
patients (5 with micro-APAs, 3 with macro-APAs) displayed partial or absent biochemical success. 
CYP11B2 immunohistochemistry of these 8 resected adrenals demonstrated the presence of a solitary 
functional macroadenoma in 3 samples. The remaining 5 adrenals comprised 1 with a solitary micro-
APA and 4 which did not have a solitary APA but showed more than one nodule with CYP11B2 
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immunostaining, with or without aldosterone-producing cell clusters [25], with the larger nodule 
considered the micro-APA.  
3.2 LC-MS/MS-based steroid profiling 
LC-MS/MS-based steroid profiling of peripheral venous plasma revealed some distinct differences 
between patients with micro-APAs, macro-APAs and BAH (Figure 2 and Table A.3, supplementary 
data). Patients with micro-APAs had lower peripheral plasma concentrations of aldosterone (P=0.006), 
18-oxocortisol (P<0.001) and 18-hydroxycortisol (P<0.001) compared with patients with macro-
APAs. The concentrations of the androgen precursor DHEAS were higher in patients with micro-
APAs versus those with macro-APAs (P=0.007). There were no significant differences in single 
steroid concentrations between patients with micro-APAs and BAH (Table A.3, supplementary data). 
Patients with macro-APAs displayed higher concentrations of aldosterone, 18-oxocortisol, 18-
hydroxycortisol (P<0.001) compared with patients with BAH (Figure 2 and Table A.3, supplementary 
data). Higher concentrations of 11-deoxycorticosterone and pregnenolone (P=0.001 and P=0.006, 
respectively) and lower concentrations of DHEA and DHEAS (P=0.010 and P=0.006, respectively) 
were measured in patients with macro-APAs relative to patients with BAH. 
Potential associations of steroids with micro-APA, macro-APA and BAH were determined by logistic 
regression models adjusting each steroid separately for sex and age to avoid a reduction of the 
predictive value of variables by collinearity (Table 1). Only steroids were entered into the model 
which displayed a significant difference between subtype in the univariate analysis (Figure 2, Table 
A.3, supplementary data). Age had no impact on diagnosis, whereas female sex was associated with an 
increased likelihood of a diagnosis of a macro-APA compared with a micro-APA and with BAH.  
With the adjustment for sex and age, only lower concentrations of 18-hydroxycortisol were associated 
with an increased likelihood of a micro-APA (OR 0.484 per ng/mL, 95% CI 0.289-0.812, P = 0.006). 
Higher concentrations of 18-hydroxycortisol were associated with an increased likelihood of a macro-
APA versus BAH (OR 2.241 per ng/mL, 95% CI 1.458-3.444, P < 0.001) (Table 1). Higher 
concentrations of aldosterone, pregnenolone and 11-deoxycorticosterone were also associated with 
macro-APAs versus BAH (Table 1). In contrast, lower concentrations of DHEA were associated with 
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an increased likelihood of a diagnosis of a macro-APA (OR 0.786 per ng/mL, 95% CI 0.656-0.941, P 
= 0.009) (Table 1). 
3.3 Random forest algorithm using steroid profiling 
Random forest classification trees were used to build a prediction model for micro-APAs, macro-
APAs or BAH using peripheral plasma steroid concentrations. The algorithm created 30 different 
classification trees to optimize the prediction model and the predictive performance of each steroid 
was estimated (Figure 3A) and the first classification tree of the forest is shown (Figure 3B). AVS and 
pathology reports identified a total of 33 micro-APAs, 11 of the 33 micro-APA were correctly 
classified by the random forest model (Figure 3C). The correct classification of macro-APAs was 
96.8% (92 of 95, with 1 patient excluded as an outlier), and 87.0% (60 of 69) of patients were 
correctly classified as BAH (Figure 3C). The overall accuracy of steroid profiling for the classification 
of the 3 groups (micro-APAs, macro-APAs and BAH) was 83.2% (163/196), and the concordant 
diagnosis of APA and BAH between steroid profiling and AVS was 88.8% (174/196) (Figure 3C). 
3.4 Diagnostic algorithm combining steroid profiling, CT and AVS 
An AVS-based approach was used for the therapeutic management of the 197 patients in this study. Of 
these patients, 128 had laparoscopic unilateral adrenalectomy for resection of an APA and 69 were 
treated with MRAs for BAH (Figure 4A). For the surgically-treated patients, 93.7% (120 of 128) 
displayed complete biochemical success after surgery. In patients with complete biochemical success, 
pathology reports indicated that the prevalence of micro-APAs was 23.3% (28 of 120 patients) and of 
macro-APAs 76.7% (92 of 120 patients). The remaining 6.3% (8 of 128 patients) displayed 
biochemical evidence of persistent hyperaldosteronism (partial or absent biochemical success). 
Assuming the patients with partial or absent biochemical success represent patients with a presurgical 
misdiagnosis of unilateral PA instead of bilateral PA, and the diagnosis of BAH with non-lateralized 
aldosterone secretion was accurate in all cases, the diagnostic accuracy of AVS-based management in 
the study cohort was 95.9% (189 of 197) (Figure 4B). 
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We tested the performance of a diagnostic algorithm using peripheral venous steroid profiling and CT 
scanning in all patients and AVS limited to patients with discordant steroid profiling and CT scanning 
results (Figure 4C). Applying this algorithm to the same cohort (n=197 patients), peripheral venous 
steroid profiling would have predicted 11 patients with micro-APAs, 112 patients with macro-APAs 
and 73 patients with BAH. Of these patients, the 11 micro-APAs were correctly classified, 11 patients 
with micro-APAs were misclassified as macro-APAs, and 9 patients with BAH were incorrectly 
classified as macro-APAs. These 31 patients would be addressed to AVS for subtype differentiation 
because of potential discordant steroid profiling and CT scanning results.  
An additional 2 of the 73 patients misclassified as BAH from steroid profiling instead of macro-APA 
would potentially be selected for AVS because of the detection of a unilateral adenoma at imaging. 
The patient with a macro-APA, classified as an outlier by steroid profiling, would also have been 
addressed to AVS. Therefore, a total of 34 patients would have AVS potentially resulting in, at the 
most, a theoretical reduction of AVS procedures by 82.7% (163 of 197 patients would bypass AVS 
assuming a normal CT morphology of the contralateral gland) with a comparable accuracy of 
diagnosis (92.4%) (Figure 4D) to that of AVS-based management. The accuracy for the correct 
classification of micro-APAs could have reached 67.9% (19 of 28, 5 patients were excluded from the 
micro-APA group because they were not biochemically cured after adrenalectomy resulting in 28 
patients with unilateral micro-APA), and the number of patients with incomplete biochemical cure 
after surgery (absent or partial biochemical success) would have decreased from 8 with the AVS 
algorithm (Figure 4B) to 6 (5.1%) with the diagnostic algorithm incorporating steroid profiling (Figure 
4D). Eleven patients with micro-APAs would have been diagnosed with BAH of which 9 were micro-
APAs (from patients with complete biochemical success after surgery) and the remaining 2 patients 
(with absent or partial biochemical success) would have received the correct treatment with a MRA 
(Figure 4D). 
4. Discussion 
We measured peripheral plasma steroid profiles by LC-MS/MS in a large series of patients with PA 
and determined the potential utility of integrating these measurements in therapeutic management. We 
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focussed on using this approach to identify patients with micro-APAs which are often missed by CT in 
those centres that rely on CT for the differentiation of APA from BAH. The similar steroid profiles of 
patients with micro-APAs and BAH limits the application of a method based on steroid measurements 
alone but when considered in a diagnostic work up that includes interpretation of CT results and AVS 
(restricted to patients with discordant steroid profiles and CT data), the theoretical algorithm 
performed almost as well as AVS alone for the diagnosis of micro-APAs.  
We also analysed the post-surgical clinical and biochemical outcomes of all patients with a unilateral 
APA (n = 128) included in the study in accordance with the PASO consensus, a standarized set of 
criteria to define outcomes of adrenalectomy for unilateral PA [26]. A smaller proportion of patients 
with micro-APAs achieved complete clinical and biochemical success than patients with macro-APAs 
but this is likely mainly due to the sex distribution difference between patients with micro-APAs 
(comprising a higher proportion of males and patients with a higher BMI) and with macro-APAs [26]. 
The sex distribution of our cohort may partially explain the difference between our findings and those 
of Omura et al., who reported an increase in the proportion of patients achieving clinical cure after 
surgical removal of micro-APAs (n = 27) compared with macro-APAs (n = 42) [18]. Although larger 
nodule size was associated with complete clinical success after adrenalectomy in a multicohort study 
[25] and APAs with KCNJ5 mutations, which tend to be larger than other APAs [32, 33], are also 
associated with favourable outcomes post-surgery [34]. 
Patients with absent or partial biochemical success after surgery were predominantly in the micro-
APA group. CYP11B2 immunohistochemistry of the resected adrenals showed that they mostly 
comprised more than one micronodule with positive CYP11B2 immunostaining, in agreement with the 
suggestion that CYP11B2 immunohistochemistry of resected adrenals may be useful as an indicator of 
biochemical outcomes and highlight patients which require ongoing follow-up with biochemical as 
well as clinical re-assessment [31]. Despite the over-representation of micro-APAs in the group of 
patients who were not biochemically cured after adrenalectomy, this nonetheless comprised only 15% 
(5 of 33) of patients with micro-APAs indicating that it is worthwhile and potentially rewarding for 
patients to have further work up for the identification of micro-APAs. 
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The small area of the resected adrenal with CYP11B2 immunostaining in micro-APAs likely explains 
the decreased presurgical plasma aldosterone concentrations of the corresponding patients compared 
with those with macro-APAs as suggested by a previous report [21]. Patients with micro-APAs also 
had lower plasma concentrations of the hybrid steroids, 18-oxocortisol and 18-hydroxycortisol, 
relative to the macro-APA group but comparable to patients with BAH. This is feasibly explained by 
the larger size of APA carrying KCNJ5 mutations [35, 36] and the association of KCNJ5-mutated 
APAs with an increased production of 18-oxocortisol and 18-hydroxycortisol [11]. In line with this, 
we show that the micro-APA group displayed a lower prevalence of KCNJ5 mutations compared with 
the macro-APA group. Further, a logistic regression model with adjustment of each steroid 
concentration for sex and age, showed an association of higher 18-hydroxycortisol concentrations (but 
not 18-oxocortisol) with an increased likelihood of a diagnosis of a macro-APA compared with micro-
APA and with BAH. The association of female sex with macro-APAs and with increasing plasma 
aldosterone concentrations is consistent with a meta-analysis report of patients with KCNJ5-mutated 
APAs displaying larger tumours and more pronounced hyperaldosteronism compared with patients 
with APAs without KCNJ5 mutations [36].  
Larger APAs may have increased glucocorticoid co-secretion [37, 38] which would be expected to 
suppress pituitary ACTH production. ACTH is the main regulator of the synthesis of DHEA and 
DHEAS and therefore increased glucocorticoid co-secretion from macro-APAs may partly explain the 
lower concentrations of these steroids observed in patients with macro-APAs compared with patients 
with micro-APAs and BAH. Additional studies are required to address the role of APA size and 
genotype on glucocorticoid co-secretion with the inclusion of plasma ACTH measurements to 
establish their effects on the steroid profile.  
In the PASO study, 6% of 699 patients did not display complete biochemical cure after adrenalectomy 
for APA and this group comprises cases of PA with bilateral asymmetrical aldosterone excess with a 
potential misdiagnosis of unilateral PA [26]. This compares favorably with CT based decision making 
for adrenalectomy, where 20% of patients with APA are not biochemically cured [39, 40]. Using AVS 
results as the reference standard, the correct diagnosis of unilateral and bilateral PA by adrenal 
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imaging (CT or magnetic resonance) was reported as 62.2% [41]. In another study on patients with 
unilateral APA (diagnosed by AVS) with follow-up data, 36% of patients who were biochemically 
cured after adrenalectomy would have been misdiagnosed on the basis of CT results [40]. Thus, 
neither CT nor AVS are completely reliable and strong interest focusses on approaches to improve the 
performance and accessibility of subtype differentiation in PA [12-17]. The potential utility of adrenal 
steroids in discriminating different subtypes of PA has been investigated in numerous studies with 
attention centering on the hybrid steroids 18-oxocortisol and 18-hydroxycortisol in urine or plasma 
[42]. Peripheral plasma 18-oxocortisol concentrations measured by LC-MS/MS can distinguish CT-
detectable APA and BAH in patients from Japan [43]. However, in a European cohort, this method 
appears to be unreliable whereas a panel of 12 adrenal steroids in peripheral plasma differentiated 
APA from BAH with an accuracy of 80% [13]. The higher production of 18-oxocortisol in patients 
with KCNJ5-mutated APAs may explain the increased performance of 18-oxocortisol for 
differentiating APA from BAH in those cohorts with higher prevalences of KCNJ5 mutations (as in 
Japan) compared with other populations (as in Europe) [13, 43].  
Genotype data in this study, as in most preceeding studies, should be interpreted with caution because 
recent evidence shows that when sequencing is targeted to areas of the adenoma that are positive for 
CYP11B2 expression, somatic mutations are detected in almost 90% of APAs [30]. Therefore, the 
non-targeted sequencing approach used here is a limitation of the current study with an 
overrepresentation of the “wild-type” genotype notably in the micro-APA group because tissue 
dissection may have missed the micronodule. Further, the macro-APA group was not defined by 
CYP11B2 immunohistochemistry but by pathology reports of the largest nodule size (which would 
have been the nodule sampled for sequencing) and may comprise CYP11B2-negative nodules with a 
wild-type genotype [33]. In these cases, a secondary nodule (or multiple APCCs) responsible for the 
pathologic aldosterone production [34, 44] would not have been sequenced. We showed by CYP11B2 
gene expression analysis of samples classified as adenomas compared with paired adjacent adrenal 
cortical tissue that the above occured but in a small minority of cases. 
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In the present study, patients with micro-APAs could not be predicted by steroid profiling alone. This 
was expected considering the high similarity we show of steroid profiles in patients with micro-APAs 
and BAH. To improve the reliability of identifying micro-APAs, we developed a hypothetical 
diagnostic algorithm integrating the additional consideration of CT imaging and using AVS only in 
patients with discordant steroid profiles and imaging data. The algorithm increased the probability of 
identifying micro-APAs whilst reducing the proportion of AVS procedures by up to 82.7% but 
achieving a comparable accuracy of diagnosis with AVS-based management.  
The strengths of our study are the large patient cohort with strict inclusion criteria for screening, 
diagnosis and subtype differentiation from 2 expert centres that use similar AVS protocols [10, 22]. 
All patients had peripheral venous steroid measurements by LC-MS/MS and assessment of post-
surgical clinical and biochemical outcomes in surgically-treated patients using the international PASO 
consensus. Further strengths are the development of an accessible online tool for the prediction of 
microAPA, macroAPA and BAH. Limitations of our study are the non-targeted genotyping approach 
and the potential inclusion of nonfunctional adenomas in the macro-APA group as discussed above 
and the relatively small number of patients with micro-APAs compared with macro-APAs and BAH. 
An additional limitation is the assumption of a correct detection of macro-APAs by CT scanning in the 
theoretical diagnostic algorithm.  
5. Perspectives 
Steroid profiling of peripheral venous plasma could potentially be used in combination with imaging 
data and AVS restricted to a small proportion of patients to identify patients in whom AVS should be 
considered mandatory. Such an approach may be useful in centres that rely on CT for subtype 
differentiation in PA because such approaches can lack the required sensitivity to detect micro-APAs.  
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Table 1. Peripheral plasma steroids associated with subtype diagnosis in primary aldosteronism 
Logistic regression analysis to identify adrenal steroids associated with micro-APAs, macro-APAs and BAH. An odds ratio greater than 1 indicates an increased 
likelihood of micro-APAs compared with BAH or compared with macro-APAs or macro-APAs compared with BAH, and an odds ratio less than 1 indicates a 
Steroids 
(per ng/mL) 
OR 
(95% CI) P value 
OR 
(95% CI) P value 
OR 
(95% CI) P value 
Micro-APA vs. BAH 
(n = 101*) 
Micro-APA vs. Macro-APA 
(n = 127*) 
Macro-APA vs. BAH 
(n =162*) 
Age 0.992 (0.949-1.036) 0.713 0.969 (0.928-1.011) 0.148 1.021 (0.985-1.058) 0.253 
Sex (ref: female) 0.674 (0.228-1.992) 0.476 0.209 (0.076-0.572) 0.002 3.015 (1.433-6.343) 0.004 
Aldosterone 11.215 (0.682-184.508) 0.091 0.422 (0.045-3.969) 0.451 877.947 (23.235-33172.977) < 0.001 
Age 0.995 (0.953-1.038) 0.813 0.966 (0.925-1.009) 0.116 1.022 (0.989-1.056) 0.201 
Sex (ref: female) 0.808 (0.286-2.284) 0.687 0.197 (0.072-0.541) 0.002 3.271 (1.596-6.702) 0.001 
18-Oxocortisol 1.291 (0.598-2.787) 0.515 0.761 (0.342-1.692) 0.503 2.984 (0.911-9.774) 0.071 
Age 0.993 (0.951-1.037) 0.753 0.964 (0.920-1.010) 0.122 1.019 (0.985-1.055) 0.279 
Sex (ref: female) 0.772 (0.275-2.171) 0.624 0.253 (0.087-0.738) 0.012 2.651 (1.241-5.662) 0.012 
18-Hydroxycortisol 0.925 (0.528-1.623) 0.787 0.484 (0.289-0.812) 0.006 2.241 (1.458-3.444) < 0.001 
Age 0.991 (0.949-1.035) 0.686 0.969 (0.928-1.011) 0.141 1.019 (0.986-1.054) 0.257 
Sex (ref: female) 0.694 (0.236-2.040) 0.507 0.198 (0.073-0.542) 0.002 3.225 (1.562-6.658) 0.002 
11-Deoxycorticosterone 8.194 (0.300-223.625) 0.212 0.807 (0.266-2.452) 0.705 137.637 (3.052-6207.424) 0.011 
Age 0.994 (0.953-1.038) 0.790 0.961 (0.920-1.004) 0.077 1.024 (0.990-1.060) 0.165 
Sex (ref: female) 0.794 (0.281-2.242) 0.664 0.198 (0.071-0.554) 0.002 3.363 (1.619-6.988) 0.001 
Pregnenolone 1.062 (0.799-1.413) 0.677 0.743 (0.547-1.008) 0.057 1.486 (1.149-1.923) 0.003 
Age 0.978 (0.933-1.025) 0.354 0.974 (0.930-1.021) 0.274 0.988 (0.950-1.027) 0.538 
Sex (ref: female) 0.786 (0.276-2.238) 0.652 0.195 (0.071-0.532) 0.001 3.651 (1.768-7.540) < 0.001 
DHEA 0.845 (0.673-1.060) 0.146 1.068 (0.868-1.315) 0.534 0.786 (0.656-0.941) 0.009 
Age 0.988 (0.941-1.038) 0.641 0.983 (0.937-1.031) 0.477 0.995 (0.956-1.035) 0.793 
Sex (ref: female) 0.720 (0.242-2.142) 0.555 0.245 (0.086-0.699) 0.009 2.646 (1.249-5.607) 0.011 
DHEAS 1.000 (0.999-1.001) 0.658 1.001 (1.000-1.001) 0.182 0.999 (0.998-0.999) 0.048 
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decreased likelihood. APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, 
dehydroepiandrosterone sulphate; OR, odds ratio. There were 33 patients in the micro-APA group; 94 in the macro-APA and 68 in the BAH groups. *1 patient 
from the BAH group was missing pregnenolone data and was not included and 1 patient from the macro-APA group had outlier steroid profiling data. 
  
 
Figure 1 CYP11B2 immunohistochemistry micro-APA and macro-APA  
The histopathology of resected adrenals from patients with a micro-APA (Panels A, B, C and D) or a 
macro-APA (Panels E and F) are shown with hematoxylin and eosin (H&E) staining (Panels A, C 
and E) and CYP11B2 immunostaining (Panels B, D and F). Micro-APAs in this study were classfied 
as a single micro-APA (diameter < 10 mm, as indicated by a single arrow in panel B) or the largest 
CYP11B2 positive nodule (with diameter < 10 mm, as indicated by a single arrow in panel D) in an 
adrenal with more than one nodule with CYP11B2 immunostaining. An example of a macro-APA is 
indicated with a double arrow in panel F. Scale bar = 2 mm. CYP11B2, aldosterone synthase; H&E, 
hematoxylin and eosin. 
 1 
 
 
 
 
 
 
 
 
Figure 2 Peripheral plasma steroid concentrations in patients with micro-APAs, macro-APAs 
and BAH 
The box and whisker plots (Panels A-G) represent peripheral plasma concentrations of the indicated 
steroids in patients with PA stratified for APA according to tumor diameter (micro-APAs ≤10 mm 
(n=33) and macro-APAs >10 mm (n=95)) and BAH (n=69). Only steroids with significant differences 
in concentrations between micro-APAs, macro-APAs and BAH are shown. Horizontal lines within 
boxes indicate the median, boxes and whiskers represent the 25th to 77th percentiles and the minimum 
and maximum values, respectively, after exclusion of outliers that are defined by 1.5 times the 
interquartile range and are indicated by filled circles. Concentrations are indicated in ng/mL which are 
converted to pmol/L by dividing by the molecular weight of each steroid: aldosterone, 360.44; 18-
oxocortisol, 376.45; 18-hydroxycortisol, 378.46; 11-deoxycorticosterone, 330.46; pregnenolone, 
316.48; DHEA, 288.42; DHEAS, 367.50. P values were calculated using Kruskal-Wallis tests 
followed by pairwise comparisons. 18OH-cortisol, 18-hydroxycortisol; APA, aldosterone-producing 
adenoma; BAH, bilateral adrenal hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, 
dehydroepiandrosterone sulfate.  
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Figure 3 Peripheral venous steroid profiling for the classification of micro-APAs, macro-APAs 
and BAH  
The random forest algorithm constructed performance estimates for each steroid (Panel A), the first 
classification tree of the forest is shown for the prediction of micro-APAs, macro-APAs and BAH 
(Panel B), and a table with the estimated classification by steroid profiling and the actual classification 
by AVS (to differentiate BAH from APA) and pathology reports (to differentiate micro-APAs from 
macro-APAs) (Panel C). One patient had outlier steroid profiling results and was omitted. Numbers 
indicate steroid concentrations in ng/mL. To convert concentrations in ng/mL to pmol/L, 
concentrations should be divided by the molecular weight of each steroid. Molecular weights: 11-
deoxycorticosterone, 330.46; 17-hydroxyprogesterone, 330.46; 18-hydroxycortisol, 378.46; 18-
oxocortisol, 376.45; aldosterone, 360.44; corticosterone, 346.46; cortisol, 362.46. 17-OH-
progesterone, 17-hydroxyprogesterone; 18OH-cortisol, 18-hydroxycortisol; APA, aldosterone-
producing adenoma; BAH, bilateral adrenal hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, 
dehydroepiandrosterone sulphate. 
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Figure 4 Clinical management algorithms for patients with primary aldosteronism  
The AVS-based management of patients in this study is shown (Panel A), and results in the accurate 
differentiation of APA from BAH in at best 95.9% of patients (assuming a correct diagnosis of all 
patients with BAH) (Panel B). The diagnostic accuracy of APA is assessed here by the proportion of 
patients with biochemical cure (120 of 128 patients with complete biochemical success). No 
biochemical cure was observed in 6.3% (8 of 128 patients with absent or partial biochemical success). 
Therapeutic management based on peripheral venous steroid profiling and CT scanning with AVS in a 
restricted subset of patients (patients with discordant CT and steroid profiling results) would have 
reduced AVS procedures by at most 82.7% (34 of 197 patients addressed to AVS) and potentially 
92.4% of patients would have had an accurate differentiation of APA from BAH (Panel C). The 
patient with outlier steroid profiling results would have been addressed to AVS. The number of 
patients with an absent or partial biochemical outcome would have been reduced to 6 (5.1%, 6 of 117) 
(Panel D). Numbers in bold indicate numbers of patients. APA, aldosterone-producing adenoma; 
AVS, adrenal venous sampling; CT, computed tomography; MRA, mineralocorticoid receptor 
antagonist; PA, primary aldosteronism. 
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Figure A.1 CYP11B2 gene expression analysis of APAs versus adjacent cortex 
 
 
 
 
 
 
 
 
 
 
 
 
Real-time TaqMan qPCR was used to compare CYP11B2 gene expression levels in samples classified 
as micro-APAs or macro-APAs compared with the respective paired adjacent cortical tissue (Adjacent 
cortex). Gene expression levels were calculated by the 2-∆∆Ct quantification method using GAPDH as 
the endogenous reference gene. We included in the analysis all samples with available adenoma and 
corresponding adjacent cortical tissue. The samples comprised 8 micro-APAs (1 KCNJ5 mutated, 7 
wild type) and 32 macro-APAs (12 KCNJ5 mutated, 6 with ATP1A1 or ATP2B3 mutations, 2 with 
CACNA1D mutations and 6 wild type). The box plots show fold-changes in gene expression (mRNA 
levels) of CYP11B2 in the indicated tissue sample. Horizontal lines within boxes indicate the median, 
boxes and whiskers represent the 25th to 77th percentiles and the minimum and maximum values, 
respectively, after exclusion of outliers that are defined by 1.5 times the interquartile range and are 
indicated by filled circles. Levels of significance are indicated. 
 
CYP11B2 gene expression analysis indicated an absence of CYP11B2 gene upregulation in 1 of the 8 
samples classified as micro-APAs (tumour-to-adjacent tissue CYP11B2 expression ratio = 0.934; 
genotype determined as wild type) and in 1 of 32 samples classified as macro-APAs (tumour-to-
adjacent tissue CYP11B2 expression ratio = 0.926, genotype determined as wild type). This indicates 
the missed dissection of the CYP11B2 positive nodule for the micro-APA and the dissection of a 
nonfunctional adenoma as the largest nodule for the sample classified as a macro-APA. 
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Table A.1 Gene mutation analysis of APAs 
Gene Name NCBI Reference Target 
Exon 
Primer sequence (5’-3’) Product 
size 
KCNJ5 NM_000890 2 Forward: gcttcatttggtggctcatt 
Reverse: gagatgactgcgttgttgga 
313 
ATP1A1 NM_000701 4 Forward: tatattgccttgtaagtgctgg 
Reverse: gaagtgggagacaaagacgg 
334 
ATP1A1 NM_000701 8 Forward: cgtggcttccttcaggttag 
Reverse: agagtgtaacattcgtgcaagc 
386 
ATP2B3 NM_021949 8 Forward: ttcttccctcttcctgtccc 
Reverse: ttcttaccccagtttccgag 
345 
CACNA1D NM_001128839 6 Forward: gtaaaggaggcatggttagg 
Reverse: tggctcagtaaatgtgctggt 
375 
CACNA1D NM_001128839 8 Forward: ttgaattgccctgggtgtat 
Reverse: aatgtctggcaacccctctt 
189 
CACNA1D NM_001128839 14 Forward: gtcctgcatgggtgttctga 
Reverse: acgaagtgcttttcggggaa 
290 
CACNA1D NM_001128839 16 Forward: taacacttgggacggtcac 
Reverse: ccatgatccacaaagcagc 
367 
CACNA1D NM_001128839 23 Forward: cacgctaactgtgcaggga 
Reverse: tcagctctgcccagaagag 
279 
CACNA1D NM_001128839 27 Forward: ccaatctacaaccaccgcgt 
Reverse: gaccaagggacagaagccaa 
198 
CACNA1D NM_001128839 32 Forward: acggttcttcctcactgtcg 
Reverse: cttcagcagaggcatttggct  
338 
 
The forward and reverse primers used to amplify exons 2 of KCNJ5 and the forward primers for the 
amplification of exons 8 and 27 of CACNA1D anneal within the respective exons (indicated in bold) and result 
in partial amplification of exons. For KCNJ5, a 323 bp 5’ fragment and a 311 bp 3’ fragment of exon 2 is not 
amplified and for CACNA1D, exon 8, a 19 bp fragment at the 5’ end is not amplified and for exon 27, a 43 bp 5’ 
fragment is not amplified. The CACNA1D primers detect all mutations described in Prada et al [1] except 
Glu412Asp mutation that is encoded by exon 9 [2] but includes the recently described Val259Gly mutation 
encoded by exon 6 by Nanba et al [3].  
Table A.2 Demographic and clinical characteristics of patients with micro-APAs, macro-APAs and BAH 
VARIABLE 
  Diagnosis  Pairwise Comparison (P value) 
N 
Total 
(n=197) 
Micro-APA 
(n=33) 
Macro-APA 
(n=95) 
BAH 
(n=69) 
Overall  
P value 
Micro-APA  
vs.  
Macro-APA 
Micro-APA 
vs.  
BAH 
Macro-APA  
vs.  
BAH 
Age (years) 197 51 [44-58] 52 [44-57] 52 [44-58] 49 [42-58] 0.647 NA NA NA 
Sex (Female) 75 75 (38.1%) 7 (21.2%) 50 (52.7%) 18 (26.1%) <0.001 0.002 0.592 0.001 
BMI (kg/m2) 196 28.0±4.4 29.3±3.8 27.1±4.6 28.5±4.2 0.027 0.046 1.000 0.174 
BASELINE PARAMETERS        
Aldosterone (pmol/L) 197 722 [466-1235] 663 [516-1243] 968 [583-1462] 508 [369-790] <0.001 0.158 0.086 <0.001 
DRC (mU/L) 124 3.5 [2.0-9.6] 3.3 [2.0-9.5] 3.1 [2.0-10.0] 4.1 [2.5-9.7] 0.480 NA NA NA 
PRA (pmol/L/min) 73 2.6 [1.6-5.1] 2.6 [2.6-6.4] 2.6 [1.3-3.8] 2.6 [1.4-6.4] 0.848 NA NA NA 
ARR_DRC 124 119 [55-273] 166 [71-346] 169 [57-357] 93 [51-146] 0.026 1.000 0.097 0.051 
ARR_PRA 73 377 [204-590] 366 [212-498] 416 [245-810] 238 [158-460] 0.100 NA NA NA 
Lowest serum K+ (mmol/L) 196 3.2 [2.8-3.6] 3.2 [2.8-3.3] 2.9 [2.5-3.2] 3.5 [3.3-3.9] <0.001 0.318 <0.001 <0.001 
Systolic BP (mmHg) 197 158 [144-175] 160 [148-175] 155 [144-180] 158 [141-170] 0.510 NA NA NA 
Diastolic BP (mmHg) 197 98 [89-106] 100 [90-106] 98 [90-106] 98 [89-105] 0.878 NA NA NA 
Antihypertensive medication (DDD) 194 3.3 [2.0-5.0] 3.0 [2.1-4.4] 3.5 [2.0-6.0] 3.0 [1.5-5.0] 0.107 NA NA NA 
CLINICAL OUTCOME        
Complete 42 42 (32.8%) 4 (12.1%) 38 (40.0%) NA 0.003 NA NA NA 
Partial 67 67 (52.4%) 21 (63.6%) 46 (48.4%) NA 0.132 NA NA NA 
Absent 19 19 (14.8%) 8 (24.3%) 11 (11.6%) NA 0.091 NA NA NA 
BIOCHEMICAL OUTCOME        
Complete 120 120 (93.8%) 28 (84.8%) 92 (96.8%) NA 0.023 NA NA NA 
Partial 4 4 (3.1%) 2 (6.1%) 2 (2.1%) NA 0.292 NA NA NA 
Absent 4 4 (3.1%) 3 (9.1%) 1 (1.1%) NA 0.036 NA NA NA 
 8 
RESECTED ADRENAL 
Size at pathology 
       
Largest nodule diameter (mm) 128 14 [9-18] 7 [5-9] 15 [12-20] NA <0.001 NA NA NA 
Genotype 125 125 31 94 NA     
Wild-type* 59 59 (47.2%) 25 (80.7%) 34 (36.2%) NA <0.001 NA NA NA 
KCNJ5 46 46 (36.8%) 1 (3.2%) 45 (47.9%) NA <0.001 NA NA NA 
CACNA1D 9 9 (7.2%) 4 (12.9%) 5 (5.3%) NA 0.310 NA NA NA 
ATP1A1+ATP2B3 11 11 (8.8%) 1 (3.2%) 10 (10.6%) NA 0.369 NA NA NA 
 
Quantitative normally distributed variables are expressed as means with SDs and quantitative non-normally distributed variables are reported as medians and interquartiles. Categorical 
variables are presented as absolute numbers and percentages. P values are calculated using Chi-square and Fisher’s exact tests or ANOVA followed by Bonferroni tests or Kruskal-
Wallis tests followed by pairwise comparisons as appropriate. APA, aldosterone-producing adenoma; ARR, aldosterone-to-renin ratio; BAH, bilateral adrenal hyperplasia; BMI, body 
mass index; BP, blood pressure; DDD, defined daily dose (defined daily dose is the assumed average maintenance dose per day for a drug used from its main indication in adults 
according to ATC/DDD Index 2018 https://www.whocc.no/atc_ddd_index/); DRC, direct renin concentration; K, potassium; N, number; NA, not applicable; PRA, plasma renin activity. 
*Wild-type indicates absence of mutations in KCNJ5, CACNA1D, ATP1A1 and ATP2B3. 
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Table A.3 Peripheral plasma steroid concentrations in patients with micro-APAs, macro-APAs and BAH 
Steroids (ng/mL) Micro-APA (n=33) 
Macro-APA 
(n=95) 
BAH 
(n=69) 
Overall 
P value 
Pairwise Comparison (P value) 
Micro-APA 
vs.       
Macro-APA 
Micro-APA 
vs.  
BAH 
Macro-APA 
vs.  
BAH 
Aldosterone 0.090 [0.038-0.149] 0.140 [0.094-0.280] 0.070 [0.033-0.123] <0.001 0.006 1.000 <0.001 
18-Oxocortisol 0.010 [0.010-0.035] 0.080 [0.020-0.320] 0.010 [0.010-0.025] <0.001 <0.001 1.000 <0.001 
18-OH-Cortisol 0.670 [0.385-0.995] 1.640 [0.770-2.670] 0.690 [0.430-1.405] <0.001 <0.001 1.000 <0.001 
21-Deoxycortisol 0.079 [0.035-0.090] 0.030 [0.010-0.091] 0.040 [0.018-0.091] 0.250 NA NA NA 
Corticosterone 2.000 [0.600-4.500] 2.340 [1.200-4.480] 2.470 [1.160-5.500] 0.235 NA NA NA 
11-Deoxycorticosterone 0.080 [0.045-0.120] 0.110 [0.050-0.220] 0.060 [0.030-0.115] 0.002 0.461 0.637 0.001 
Progesterone 0.110 [0.060-0.180] 0.130 [0.090-0.220] 0.120 [0.080-0.215] 0.540 NA NA NA 
Cortisol 115.00 [52.50-146.50] 117.00 [66.00-152.00] 112.00 [81.00-166.00] 0.370 NA NA NA 
Cortisone 16.40 [11.95-21.45] 16.80 [12.10-19.70] 17.30 [13.55-21.60] 0.566 NA NA NA 
11-Deoxycortisol 0.310 [0.130-0.540] 0.340 [0.200-0.700] 0.290 [0.185-0.665] 0.576 NA NA NA 
17-OH-Progesterone 0.920 [0.375-1.290] 0.710 [0.400-1.140] 0.880 [0.500-1.295] 0.244 NA NA NA 
Pregnenolone 0.270 [0.170-0.700] 0.360 [0.210-3.190] 0.255 [0.188-0.413] 0.005 0.119 1.000 0.006 
Androstenedione 0.850 [0.590-1.160] 0.780 [0.500-1.330] 0.840 [0.590-1.235] 0.825 NA NA NA 
DHEA 2.579 [1.751-3.481] 1.820 [1.047-3.120] 2.584 [1.551-4.411] 0.009 0.183 1.000 0.010 
DHEAS 1210.0 [829.0-1588.0] 800.0 [444.0-1288.0] 1145.0 [689.5-1719.0] 0.001 0.007 1.000 0.006 
Quantitative normally distributed variables are expressed as means with SDs and quantitative non-normally distributed variables are reported as medians and 
interquartiles. Categorical variables are presented as absolute numbers and percentages. P values are calculated using Kruskal-Wallis tests followed by pairwise 
comparisons as appropriate. To convert concentrations in ng/mL to pmol/L, concentrations should be divided by the molecular weight of each steroid. Molecular 
weights: 11-deoxycorticosterone, 330.46; 17-hydroxyprogesterone, 330.46; 18-hydroxycortisol, 378.46; 18-oxocortisol, 376.45; aldosterone, 360.44; corticosterone, 
346.46; cortisol, 362.46. 17-OH-progesterone, 17-hydroxyprogesterone; 18OH-cortisol, 18-hydroxycortisol; APA, aldosterone-producing adenoma; BAH, bilateral 
adrenal hyperplasia; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; NA, not applicable.             
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